TuesdayMar 08, 2022 3:18 pm

Dr. Bronner’s to Provide Employees with Ketamine-Assisted Therapy

In a recent press release, Dr. Bronner’s revealed that it had broadened its mental healthcare coverage as the first step in its strategy to provide access to psychedelic-assisted therapy to its employees as a means to promote mental health. This plan, which includes the use of ketamine in combination with therapy, is to be administered by Enthea, a not-for-profit healthcare organization that is responsible for benefit plan administration, provider network management and medical policy development. The organization also establishes quality-of-care standards for provided treatments, including the management of a specialty provider network. Dr. Bronner’s is collaborating with Enthea because both…

Continue Reading

MondayMar 07, 2022 12:13 pm

Signs the Psychedelics Renaissance Is Here to Stay

It seems psychedelics are here to stay, what with the developments being seen in different parts of the country. These natural substances were being used by Indigenous communities way before the West began to embrace the use of drugs such as LSD in the ‘50s. During this period before the drugs were banned in 1970, significant research looking into psychedelic-assisted therapy was conducted, with numerous studies showing their potential in the treatment of addiction, anxiety and depression. Recently, we’ve seen psychedelics go mainstream again, thanks to new clinical trials and studies that have convinced regulatory bodies, including the U.S. FDA…

Continue Reading

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

Continue Reading

FridayMar 04, 2022 12:43 pm

Utah Legislators Advance Approved Psychedelics Bill to Governor’s Desk

Last week, legislators in the state of Utah sent a measure to the governor that would establish a task force to conduct research on the therapeutic potential of various psychedelic substances and make recommendations on potential regulations for their legal use. The bill, which was introduced by Rep. Brady Brammer, was passed by both the House and Senate, with 68 to 1 and 23 to 1 votes respectively. It remains unclear where the state’s governor, Gov. Spencer Cox, stands on this issue. The recommendations made by the panel on these substances, which are defined as controlled substances under the Controlled…

Continue Reading

ThursdayMar 03, 2022 2:17 pm

How Investors Can Cash In on the Boom in the Psychedelic Field

The psychedelic sector has seen major growth in the past few years as consumer interest in psychedelic drugs as alternative medicines has increased. As research into psychedelics picks up steam and lawmakers discuss legalizing the substances, industry experts project that the psychedelics industry will experience significant growth over the next decade. Last year was a pretty good year for the nascent sector, and a new report indicates the industry could reach even greater highs in 2022. For investors who are looking to diversify their portfolio and invest in an emerging industry, psychedelics present an attractive opportunity. According to the Defiance…

Continue Reading

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

Continue Reading

WednesdayMar 02, 2022 2:16 pm

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Teams Up with Chopra Foundation to Foster Psychedelics Therapy Awareness

Dr. Deepak Chopra recently stated that there was an urgent need for more effective treatments in the mental health space, a statement with which Doug Drysdale, CEO of Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), agrees. Drysdale stated that he believed that the largest barrier in the advancement of the flourishing psychedelics industry was the stigmatization and misinformation concerning psychedelic compounds. He explained that many individuals who weren’t involved in the psychedelics sector knew so little about these compounds and had warped perceptions about what they could do, giving the example of a conversation he had with one scientist who…

Continue Reading

TuesdayMar 01, 2022 2:18 pm

Study Finds Psilocybin Use Lowers Odds of Being Arrested

A new study has linked the use of psilocybin with a reduction in the likelihood of an individual engaging in criminal behavior. Psilocybin is the active compound found in hallucinogenic mushrooms. Harvard University clinical psychology PhD candidate Grant Jones, the author of the study, stated that his interest in psychedelics grew as the substances gained more attention because of their treatment potential, having demonstrated that they could be used to relieve a number of mental health conditions. Jones explained that the purpose of the research was to investigate the relationship between criminality and psychedelics using population-based survey data, because not…

Continue Reading

MondayFeb 28, 2022 10:29 am

At-Home Ketamine Treatments for Mental Disorders Boom in US

Ketamine for the treatment of various mental health conditions, particularly depression, is growing in the United States. However, while the ease of prescription rules is fueling increases in drug offerings, some experts are concerned that this may cause a regulatory crackdown, as the long-term impact of this particular anesthetic hasn’t been well studied. Boris Heifets, an assistant professor of anesthesiology at Stanford University, explained that it would be better if the drug was slowly rolled out to better implement a much more integrated approach to mental health. Ketamine, which was once a taboo party drug, has been available in the…

Continue Reading

MondayFeb 28, 2022 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology

Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet Delic, media properties providing education on psychedelics; and DELIC Labs, a federally-authorized research facility  The company’s CSO has spoken at a number of conferences on the importance of controlling the extraction production processes for…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050